IDH1 and IDH2 mutations in myeloid neoplasms -Novel paradigms and clinical implications
myeloid neoplasms include myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/ MPN), and acute myeloid leukemia (AML). In the last few years there have been major advances in our understanding of the molecular bases of these disorders, and molecular genetic data are increasingly being used for diagnosis, risk assessment and definition of treatment strategies. 2, 3 These data now include information on mutations in the IDH1 and IDH2 genes.
IDH1 and IDH2 encode the enzymes isocitrate dehydrogenase 1 and 2, respectively. The essential information about these genes and their products is reported in Table 1 .
Somatic mutations of IDH1 and IDH2 in malignant gliomas
In 2008, though a genome-wide analysis Parsons et al. 4 identified somatic mutations at codon 132 of IDH1 in approximately 12% of patients with glioblastoma multiforme, the most common and fatal type of brain cancer. In a subsequent study, these authors detected somatic mutations that affected amino acid 132 of IDH1 in more than 70% of gliomas. 5 In most cases, arginine 132 was mutated to histidine (R132H). Some tumors without mutations in IDH1 had mutations affecting the analogous amino acid (R172) of the IDH2 gene, strongly indicating a role of mutations in the NADP + -dependent isocitrate dehydrogenase genes in the pathogenesis of these malignancies. Overall, brain tumors with IDH1 or IDH2 mutations represented a distinctive subgroup of low-grade and secondary gliomas with a better outcome compared to that of tumors with wild-type IDH genes.
A causal relationship between acquired error in cellular metabolism and malignant transformation
Since a single copy of the gene -IDH1 or IDH2 -is mutated in human gliomas, Dang and co-workers 6 hypothesized that the mutations do not result in a simple loss of function. They did an elegant study to determine the impact of the IDH1 (R132H) mutation on cellular metabolism, and showed that it resulted in the production of 2-hydroxyglutarate. 6 Since overproduction of this metabolite is associated with a high risk of brain tumors in patients with inborn metabolic errors, the authors concluded that the accumulation of excess 2-hydroxyglutarate in vivo contributes to the formation and malignant progression of gliomas, establishing a link between abnormal metabolism and malignancy. 7 The altered metabolic pathway associat-© F e r r a t a S t o r t i F o u n d a t i o n ed with mutant IDH1 has also been shown to contribute to tumor growth by activating hypoxia-inducible factor-1a. 8 These observations have important clinical implications, as patients with initial or low-grade forms of glioma may benefit from the therapeutic inhibition of 2-hydroxyglutarate production. 
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sequences of genes, including IDH1 (R132C). Interestingly, somatic mutations at codon 132 of IDH1 were found in 15 of 187 additional AML genomes: all these mutations were heterozygous and strongly associated with normal cytogenetic status.
In the last few months, several studies have been published on somatic mutations of IDH1 and IDH2 in AML, and their main findings are summarized in Table 2 . [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Based on data reported in Table 2 , it can be concluded that:
(i) somatic mutations of IDH1 and IDH2 are found mainly, although not exclusively, in cytogenetically normal AML, in which they are -with a few exceptions -mutually exclusive. On average, about 30% of patients with cytogenetically normal AML carry a mutant IDH1 or IDH2 gene, and in this category IDH2 mutations are more common that IDH1 mutations;
(ii) the vast majority of somatic mutations of IDH1 and IDH2 involve residues R132 of IDH1, and R140 or R172 of IDH2. This allows a quick and sensitive screening for IDH1 and IDH2 mutations, 21 providing clinicians with an important diagnostic instrument;
(iii) the prognostic significance of somatic mutations of IDH1 and IDH2 in AML is currently under investigation, but the available evidence indicates that they may be associated with an intermediate to high genetic risk.
Metabolic abnormalities in acute myeloid leukemia associated with somatic mutations of IDH1 and IDH2 and potential novel therapeutic perspectives
Two recent studies showed that AML cells bearing heterozygous IDH1 or IDH2 mutations accumulate 2-hydroxyglutarate. 22, 23 This finding suggests that 2-hydroxyglutarate is an onco-metabolite that plays a role not only in the pathogenesis of gliomas but also in leukemic transformation, and might have therapeutic implications for the treatment of AML. In fact, blocking the accumulation of 2-hydroxyglutarate through the inhibition of mutant IDH enzymes could represent a therapeutic goal: for detailed information about this issue, the reader is referred to a very comprehensive review article by Dang et al. 9 A few small molecules capable of inhibiting IDH enzymes have already entered preclinical studies or clinical development.
Somatic mutations of IDH1 and IDH2 in myeloproliferative neoplasms, myelodysplastic syndromes and secondary acute myeloid leukemia
Green and Beer 24 searched for mutations in IDH1 and IDH2 in patients with AML that had evolved from JAK2-mutated MPN, and found somatic mutations in five of 16 patients: three involved IDH1 (R132) and two IDH2 (R140). These mutations were not present in 180 unselected patients with polycythemia vera or essential thrombocythemia in chronic phase. Pardanani et al. 25 detected IDH1 (R132) or IDH2 (R140) mutations in seven of 34 patients with blast-phase MPN, and in three of 166 patients with chronic-phase MPN (these latter patients had primary myelofibrosis). In a study reported in this issue of Haematologica, Andrulis et al. 26 investigated bone marrow samples from 160 patients with chronic MPN using an antibody highly specific for the IDH1 (R132H) mutation, and found three positive patients. The mutation could be confirmed by DNA sequencing in only one of these three individuals, which may have been because of a low mutant allele burden. This underscores the need for sensitive assays to detect IDH1 or IDH2 mutations in patients with 
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Conclusions
The remarkable achievements described in this perspective article have been made in the last 2-3 years, which indicates how fast our understanding of the molecular bases of myeloid neoplasms is evolving. It is to be hoped that these achievements will not only make a molecular classification of myeloid neoplasms feasible, but will also allow novel targeted therapies to be developed. 1 In lymphoid cells, CD30 is an activation marker inducible in vitro by mitogenic signals and viral stimulation, and its expression is detected in a small number of immunoblasts in benign lymphatic tissues. 2 In pathological conditions, CD30 is found at variable levels in different lymphomas of B-cell or T-cell derivation, and in several reactive conditions (Table 1) . However, strong and homogeneous CD30 expression in most neoplastic cells is restricted to fewer entities, mainly three groups of lymphoid neoplasms: (i) classical Hodgkin's lymphoma, (ii) anaplastic large cell lymphomas (ALCL), and (iii) primary cutaneous CD30 + T-cell lymphoproliferative disorders. 3 For diagnostic purposes, the detection of CD30 is of particular value as a hallmark feature, albeit not specific, for the identification of these entities.
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The disorders most characteristically associated with CD30 are distinct clinico-pathological entities -interestingly with some morphological similarity, as 'Hodgkin's-like' features may be encountered in both ALCL and primary cutaneous CD30 + lymphoproliferative disorders. Although there has been a lot of speculation in the past about the relationship and possible overlap between classical Hodgkin's lymphoma and ALCL, it is now clear that these are biologically distinct entities of different cellular derivation (B-cell versus T-cell, respectively). Historically, CD30 was instrumental in identifying ALCL as lymphomas composed of large cells showing homogeneous expression of CD30 at high levels, and characterized by cohesive growth and peculiar 'anaplastic' cytomorphological features. 4 Among these, a small subset of cases of B-cell derivation represent variants of diffuse large B-cell lymphoma. Nowadays, the designation ALCL is restricted to cases of T-cell derivation. These overall infrequent neoplasms involving lymph nodes and/or extranodal sites comprise so-called typical 'hallmark cells' -characterized by an eccentric horseshoe-shaped nucleus and a prominent eosinophilic Golgi region. Anaplastic lymphoma kinase (ALK) gene status was found to be another critical parameter to characterize two subsets of ALCL. 5 Molecularly defined ALK-positive ALCL is mostly a disease of children and young adults, carries a relatively good prognosis and comprises a morphological spectrum including variants deviating from the common type by the presence of only occasional 'hallmark' tumor cells and/or an associated reactive background. Conversely, ALK-negative ALCL affects older individuals and is associated with a worse prognosis, closer to that of peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS). 6 The view of ALK-positive and ALKnegative ALCL as two variants of the same entity evolved towards the concept of two separate disease entities in the current WHO classification of hematologic malignancies. 3 Although the majority of ALCL occur as primary systemic disorders, a subset of ALK-negative ALCL -referred to as primary cutaneous ALCL -occurs primarily as single or multifocal tumor lesions in the skin, usually remains localized to the skin, may undergo spontaneous regression and generally has a favorable prognosis. Because of overlapping clinical and pathological features with lymphomatoid papulosis, a clinically benign recurring skin lymphoproliferative disease composed of large atypical 'anaplastic' CD30 + cells admixed with an inflammatory background, both primary cutaneous ALCL and lymphomatoid papulosis are considered within the spectrum of primary cutaneous CD30 + T-cell lymphoproliferative disorders. Figure 1 provides a synoptic view of CD30 + lymphoproliferations of T-cell derivation.
A peculiar feature of ALCL is that, despite the presence of monoclonal T-cell receptor (TCR) gene rearrangement indicative of T-cell lineage derivation, its manifestations of a T-cell immunophenotype are usually limited. Indeed, ALCL tumor cells usually show reduced or absent expression of one or more T-cell antigens or
